Full-Time

Associate Director

Medical Insights and Analytics

Deadline 9/22/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$122k - $212.8k/yr

Hopewell Township, NJ, USA

Hybrid

Hybrid work is required; the role includes approximately 10% domestic travel.

Bachelor's

Category
Data & Analytics (1)
Required Skills
Dataiku
Python
SAS
Regression
Data Visualization
SQL
Financial analysis
Word/Pages/Docs
Tableau
Data Analysis
Excel/Numbers/Sheets

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A minimum of 7 years of relevant experience in analytics, data science, patient analytics, medical affairs, epidemiology, evidence generation, strategic planning, or management consulting.
  • Demonstrated success solving ambiguous business problems and generating meaningful insights and recommendations.
  • Demonstrated success in data-driven insight storytelling, data visualization, and developing effective presentations to translate insight into actions for the brand.
  • Expertise in pharmaceutical data sets, including Rx claims, medical claims, patient-level data, electronic health record data, and census data.
  • Pharmaceutical or healthcare industry experience.
  • Strong leadership agility and cross-functional partnering skills.
  • A general management mindset, business acumen, and strategic thinking skills.
  • Diversity of experience with demonstrated learning agility to move across different stakeholders.
  • A high degree of intellectual curiosity.
  • Proficiency with Microsoft applications, including Excel, Word, and PowerPoint, and Tableau.
  • Approximately 10% domestic travel is required.
Responsibilities
  • Lead the design, development, implementation, and prioritization of the strategic analytics and reporting approach for the Neuroscience Medical Affairs team.
  • Manage the development and implementation of dashboards, including identifying patient care gaps, monitoring Neuroscience Medical Affairs field engagements, and measuring initiatives related to Neuroscience Medical Affairs strategic imperatives.
  • Assess emerging trends in patient outcomes, health equity, population health, and stakeholder unmet needs.
  • Integrate analytical findings with secondary intelligence, Neuroscience Medical Affairs field input, primary research, and other insights to identify areas supporting key customer needs.
  • Partner across teams to enhance medical engagement through data-driven insights, increase scientific share of voice, address unmet needs, and improve patient outcomes.
  • Provide input to strategic and business plans, Neuroscience Medical Affairs strategies, and evidence generation plans.
  • Cultivate strong external partnerships and identify new data sources that enhance decision-making.
  • Partner across functions and organizational levels to compliantly integrate information into analysis and assessments of Neuroscience Medical Affairs strategies and tactics.
  • Stay abreast of emerging healthcare and pharmaceutical industry trends and assess their potential impact on Neuroscience Medical Affairs strategies.
Desired Qualifications
  • An advanced degree.
  • Experience or background in clinical data, research, and/or scientific exchanges.
  • Experience utilizing advanced data processing tools such as SAS, SQL, Dataiku, and Python.
  • Ability to execute basic statistical methods such as Test and Control and regression.
  • Commitment to learning and applying emerging technologies such as artificial intelligence.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.